Marcy l'Etoile (France) and Cambridge, Massachusetts (US) - 21 April 2010 - Exclusive agreement to...
Kyoto, Japan and Marcy l’Etoile, France – 21 May 2010 – Shimadzu and bioMérieux announce today that they have entered into a partnership to commercialise a mass spectrometry system for bacterial identification in microbiology laboratories. bioMérieux will work with Shimadzu and their subsidiary, Kratos Analytical, to adapt their linear MALDI-TOF* mass spectrometry technology for optimised integration into the microbiology laboratory workflow. This new solution is planned for commercialisation by bioMérieux in 2010, together with the microbial database acquired from AnagnosTec.
Shimadzu has developed a broad range of technologies, encompassing analytical and measuring instruments, including liquid chromatographs, mass spectrometers, spectrophotometers and life science instruments, across many fields. The company has a long experience in mass spectrometry, including pioneering work in the development of MALDI-TOF mass spectrometry technology.
As the world leader in microbiology, bioMérieux will bring its expertise in infectious diseases and extensive library of microorganisms. The company is constantly expanding its product offering to meet the diverse needs of microbiology labs and this new identification solution will be fully integrated with bioMérieux’s VITEK®, the world’s leading platform for identification and antibiotic susceptibility testing (AST).
“We are very proud to announce our collaboration with bioMérieux, and we expect to make a significant contribution to the field of bacterial identification as a result,” said Osamu Ando, general manager for the analytical and measuring instruments division at Shimadzu Corporation. “Over the past few years, MALDI-TOF MS has become a key part of our product range, and is driving the expansion of our life science business. This collaboration with bioMérieux represents a new phase in the evolution of our business by expanding it from the research market into diagnostic testing.”
“We are very pleased to be partnering with Shimadzu, a leader in mass spectrometry and innovative technologies,” said Thierry Bernard, corporate vice president, global commercial operations at bioMérieux. “By combining Shimadzu’s expertise and our unique understanding of the microbiology laboratory, bioMérieux will be the only company to provide a solution integrating mass spectrometry for bacterial ID with the market’s fastest AST on VITEK 2. This complete offer, including the new Myla™ middleware, clearly demonstrates bioMérieux’s commitment to enhance productivity in the lab,” he added.
*About Matrix-assisted laser desorption / ionisation time-of-flight mass spectrometry
In MALDI-TOF, the sample to be analysed is mixed with another compound, called a matrix. The mixture is applied to a metal plate and irradiated with a laser. The matrix absorbs the laser light and vaporises, along with the sample, in the process gaining an electrical charge (ionisation).
Electric fields then guide the ions into the time-of-flight mass spectrometer which separates them according to ‘weight’ (mass) and displays the results as a series of lines (spectrum) which correspond to different fragments that have broken away from the original molecule. By analysing the pattern of fragments it is possible to deduce the structure of the molecule.
The system proposed in this collaboration takes this further by comparing the sample spectrum to a database of spectra from a growing number of bacterial species to allow the system to accurately identify the species in question.
Founded in 1875, Shimadzu Corporation, a leader in the development of advanced technologies, has a distinguished history of innovation built on the foundation of contributing to society through science and technology. Shimadzu presently offers a multitude of products, encompassing analytical and measuring instruments, medical systems and equipment, aircraft equipment and industrial equipment, across a wide range of fields, as well as meticulous, responsive service. They maintain a global network of sales, service, technical support and applications centres on six continents, and have established long-term relationships with a host of highly trained distributors located in over 100 countries.
Other information can be found at Shimadzu’s website.
Philips and bioMérieux Announce Partnership to Develop and Market Next-Generation Handheld Diagnostic Solutions for Point-of-Care
Fully automated handheld diagnostic test devices designed to improve diagnosis and disease management in critical...
Marcy l'Etoile, France, 12 November 2009 - A world leader in the field of in...
Methicillin-resistant Staphylococcus aureus (MRSA) is the most prevalent multi-drug resistant bacteria and a growing threat...